Introduction
Although improvement in erectile function (EF) is paramount in the treatment of erectile dysfunction (ED), the impact of the disease is multifaceted, and includes a myriad of physical and psychosocial aspects not addressed by improvement of EF alone. 1 In fact, one of the first concerns of men who choose to undergo treatment is for their partner's sexual satisfaction. [2] [3] [4] The importance of sexual satisfaction in the treatment of ED is reflected by the definition of ED from the National Institutes of Health consensus panel, where ED is defined as the inability to achieve and maintain an erection sufficient for satisfactory sexual intercourse. 5 In a pooled analysis of tadalafil taken-as-needed studies, Sexual Encounter Profile (SEP) diaries were used for both participants and their partners. Both participants and partners reported greater overall satisfaction (OS) with the sexual experience with tadalafil than with placebo. 6 In another pooled analysis, flexible-dose vardenafil taken as needed improved sexual functioning and treatment satisfaction (THX) for men with ED and their partners. 7 To further support exploration of the relationship between ED treatment and partner satisfaction, another study reported that women whose partners were taking phosphodiesterase 5 inhibitors were more satisfied with their sexual experiences than women whose partners were not taking phosphodiesterase 5 inhibitors. 8 Although the efficacy of tadalafil taken once daily has been shown, its impact on men's sexual satisfaction, confidence and self-esteem, or their female partner's satisfaction, has not yet been reported. As sexual intercourse involves both a man and his partner, the authors hypothesize that successfully treating a man with ED would also impact his partner and their relationship. This study was designed to evaluate the efficacy of tadalafil 5 mg once daily in improving EF in men with ED, sexual quality of life (SQoL) and sexual satisfaction of the participant and his partner, and psychosocial outcomes of the participant.
Methods
The primary outcomes (efficacy and SQoL of participants and partners) of this multicenter, doubleblind, placebo-controlled, parallel group study (Study H6D-MC-LVGH) have been reported elsewhere. 9 The psychosocial outcomes and sexual satisfaction results for the participant and his partner are reported here. This 12-week study of tadalafil 5 mg once daily was completed in January 2008 at 26 sites in Austria, Germany, France, Mexico and the United States in accordance with regulatory standards of Good Clinical Practice and the Declaration of Helsinki (1996) . The study protocol was approved by each institution's Investigational Review Board or Independent Ethics Committee, and all participants and their partners provided a written informed consent before undergoing any protocol-specific procedures or receiving any study treatment.
Participants
Participants who were eligible to participate in this study were X18 years of age who reported a history of ED of X3-month duration, anticipated having the same adult female sexual partner during the study period, agreed to make X4 sexual intercourse attempts with their female partner during the 4-week run-in phase and agreed not to use any other ED treatments during the study. Eligible female partners were X18 years of age and had adequate sexual functioning as determined by a Female Sexual Function Index total score of 426.55.
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Exclusion criteria for participants included previous or current tadalafil treatment, ED caused by primary sexual disorders, including premature ejaculation or ED caused by untreated or inadequately treated endocrine disease (for example, hypopituitarism, hypogonadism or uncorrected hypothyroidism), history of radical prostatectomy or other pelvic surgery with subsequent failure to achieve an erection, stroke, unstable cardiovascular status, clinically significant renal insufficiency or hepatobiliary disease, and hemoglobin A1c 413% at screening. Exclusionary medications included nitrates, cancer chemotherapy, or antiandrogens (except finasteride or dutasteride) and phosphodiesterase 5 inhibitors judged by the investigator to be ineffective.
Study design
During a 4-week run-in period, participants did not use any form of ED treatment. Participants' partners were required to attend only visits 1 and 4. During visit 2 after the run-in period, participants who met enrollment criteria were stratified by ED severity, as defined by their baseline International Index of erectile function (IIEF-EF) score (mild EDX17, moderate ED ¼ 11-16, severe EDp10). 11, 12 These participants were then randomly allocated within each geographical region and severity group to receive either tadalafil 5 mg or placebo once daily in a 3:1 ratio. This ratio was used to increase the number of participants exposed to active treatment and to collect additional information on the effect of treatment on the study measures. A personal digital assistant system was used to collect participants' and partners' responses to the study measures; each person had their own personal code that gave them access to enter data specific to that individual. Data were stored in a designated vendor database system.
Study outcomes
The scope of this report includes several instruments that measure psychosocial outcomes and sexual satisfaction. Only the domains of the instruments directly measuring satisfaction and those that could impact satisfaction are reported.
The validated Sexual Life Quality Questionnaire (SLQQ), which includes a separate version for men and women, is a multidimensional instrument that consists of two domains, SQoL (10 questions) and THX (6 questions). The SQoL domain compares the sexual experience of the participant or his partner at the time of the study with their experience before the onset of the participant's ED. 13 The overall results from the SQoL and THX domains are presented in this report. The SLQQ-THX domain has a raw score (1-6 range); these scores were converted to a scale of 0 to 5 by subtracting 1 from each response, then each transformed score was multiplied by 20 to produce a standardized score ranging from 0 to 100. The SLQQ-THX score for a respondent was derived from the mean of the standardized item scores when X4 of 6 items in this domain were completed.
The participant's psychosocial outcomes were measured by the Self-Esteem And Relationship (SEAR) questionnaire, which consists of 14 items divided into two domains, including sexual relationship and confidence. [14] [15] [16] The confidence domain is subdivided into self-esteem and overall relationship subscales. The total, domain and subscale scores of the SEAR questionnaire were computed by summing their respective items and standardizing them to a 0 to 100 scale (100 Â (actual raw scoreÀlowest possible raw score)/possible raw score range). 17 Any individual domain or subscale
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Other satisfaction measures included were SEP questions 4 (SEP4) and 5 (SEP5) for the participant (SEP4, Were you satisfied with the hardness of your erection? and SEP5, Were you satisfied overall with this sexual experience?) and SEP question 3 for the partner (pSEP3, Were you satisfied overall with this sexual experience?).
The IIEF, a well-validated measure consisting of 15 questions and five domains, has been widely used in ED studies. The questions in the measure apply to the previous 4 weeks, and higher scores represent greater satisfaction. 18 In addition to the EF domain, IIEF-IS (intercourse satisfaction) and IIEF-OS domains of the IIEF were used to assess the participant's satisfaction. The IS domain has a maximum possible score of 15 and consists of question 6 (How many times have you attempted sexual intercourse?), question 7 (When you attempted sexual intercourse, how often was it satisfactory for you?) and question 8 (How much have you enjoyed sexual intercourse?). The maximum score for the OS domain is 10 and consists of question 13 (How satisfied have you been with your overall sex life?) and question 14 (How satisfied have you been with your sexual relationship with your partner?).
Statistical analysis
The co-primary efficacy measures included changes in IIEF-EF domain score, SEP2 and SEP3 responses, in addition to participant and partner SLQQ-QoL (quality of life) domain scores. 9 With an estimated 30% initial screening failure rate and an expected 20% drop out rate after randomization, a total of 450 participants were required for screening to ensure that 320 participants were randomized to either tadalafil 5 mg or placebo and 250 participants completed the study. This sample size provided at least 95% power to detect treatment group differences in mean change from baseline of 7.5 points, 25% and 30% in IIEF-EF, SEP2 and SEP3 between participants treated with tadalafil 5 mg vs placebo, assuming a common standard deviation of 10 points, 35% and 40%, respectively.
After adjusting for multiple comparisons, it was further assumed that the difference in mean change from baseline score of participants and partners on the SLQQ-QoL between tadalafil 5 mg and placebo was 15, with a common standard deviation equal to 25. For analysis of the scores for IIEF-IS and IIEF-OS, SEAR for participants, and participant and partner SLQQ-QoL, the last-observation-carried-forward convention was used. Changes from baseline for IIEF-IS and IIEF-OS, SEP4 and SEP5, SEAR for participants, pSEP3 for partners, and participant and partner SLQQ-QoL were analyzed using ANCO-VA (analysis of covariance) models. The models included terms of treatment group, pooled site, baseline value for each efficacy variable and baseline-by-treatment interaction (if the interaction term was significant, Po0.10). Results from SLQQ-THX domain were also analyzed using the ANCOVA model that included similar terms as previous ANCOVA models, with the exception of the baseline IIEF-EF domain value. Pearson correlation coefficients were explored for each treatment group separately to assess the association between change in participant's EF and change in participant's satisfaction, psychosocial outcomes and SQoL, in addition to the association between change in men's EF, and improvements in their female partners' satisfaction and SQoL.
Safety analyses included all randomized participants. Safety was assessed by evaluating adverse events and changes in vital signs. Adverse events were summarized by preferred term for severity and relationship to study drug.
Results

Participant and partner characteristics
The participant's baseline characteristics were published previously. 9 The mean age of all participants was 54 (s.d. ¼ 10) years, and most participants had ED for at least 1 year (Table 1 ). There were no statistically significant treatment group differences when comparing demographics and baseline medical characteristics. Most participants (76% tadalafil, 74% placebo) reported ED that was mild or moderate in severity with a mixed etiology (organic/psychogenic) of ED (43% tadalafil, 44% placebo).
For the female partners, baseline demographics were similar across the treatment groups. The mean age of partners in the tadalafil and placebo groups was 51 (s.d. ¼ 11) and 50 (s.d. ¼ 12) years, respectively. The majority (72%) of partners were Caucasians. The partners' mean total baseline Female Sexual Function Index score was 31 (s.d. ¼ 2, range 27-36) for the tadalafil and placebo groups; this assured that partners with adequate sexual function were enrolled.
Treatment satisfaction
As measured by the SLQQ-THX domain, participants who received tadalafil were significantly more satisfied with treatment compared with placebo (75 vs 51, Po0.001). Likewise, the partners of tadalafiltreated participants were significantly more satisfied with treatment compared with placebo (73 vs 55, Po0.001) (Figure 1 ). (Figure 2 ). The mean increase in the SEAR total score for participants was 30 (tadalafil) vs 5 (placebo) (Po0.001). Minimal clinical meaningful improvement has been reported to be 10 points on most aspects of the SEAR.
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Sexual life quality questionnaire-quality of life The SLQQ-QoL data for this study were reported previously; briefly, treatment with tadalafil significantly improved participants' and partners' SQoL. 9 The mean increase in SLQQ-QoL scores for tadalafiltreated participants (27 to 66) was significantly greater than that for the placebo (28 to 40) (Po0.001). Similarly, the mean increase in scores among the female partners of tadalafil-treated participants (35 to 67) was significantly greater compared with placebo (39 to 44) (Po0.001).
Participant satisfaction
Tadalafil-treated participants reported significantly improved OS (SEP5 and IIEF-OS), IIEF-IS, and satisfaction with erection hardness (SEP4) compared with participants randomized to placebo. When all intercourse attempts were considered (SEP3 positive or negative), participants treated with tadalafil reported significantly greater satisfaction with erection hardness and overall sexual satisfaction compared with placebo (mean perparticipant percentage of 'yes' responses to SEP4 and SEP5 during the treatment period were 57 and 56% for tadalafil vs 20 and 20% for placebo, respectively, Po0.001). When all successful intercourse attempts were considered (SEP3 positive), tadalafil-treated participants also reported significantly greater satisfaction with erection hardness and overall sexual satisfaction compared with placebo (mean per-participant percentage of 'yes' responses to SEP4 and SEP5 during the treatment period were 77 and 74% for tadalafil vs 56 and 52% for placebo, respectively, Po0.001) (Figures 3 and 4) . The mean increases in IIEF-OS and IIEF-IS domain scores from baseline to end point were 3 vs 0.5 and 3 vs 0.1 (Po0.001) for tadalafil vs placebo, respectively ( Figure 5 ).
Partner satisfaction
Partners of tadalafil-treated participants reported significantly greater overall sexual satisfaction (pSEP3) for all intercourse attempts compared with partners of placebo-treated participants (mean perpartner percentage of 'yes' responses to pSEP3 during the treatment period were 70% for tadalafil vs 37% for placebo, Po0.001) (Figure 3 ). Among the participants who reported X1 successful Figure 1 Overall Sexual Life Quality Questionnaire (SLQQ)-treatment satisfaction for participants and partners. * P-value o0.001 (compared with placebo).
Sexual satisfaction of participants and partners AD Seftel et al intercourse attempts during the treatment period (participant SEP3 positive), partners of tadalafiltreated participants reported greater overall sexual satisfaction compared with partners of placebotreated participants (mean per-partner percentage of 'yes' responses to pSEP3 during the treatment period were 89% for tadalafil vs 76% for placebo (Po0.001)). Table 2) . Figure 3 Overall sexual satisfaction for participants and partners. SEP, sexual encounter profile; SEP3, Did your erection last long enough for you to have successful intercourse? SEP5, Were you satisfied overall with this sexual experience? pSEP3 (partner), Were you satisfied overall with this sexual experience? *P-value o0.001 (compared to placebo). y P-value o0.001; P-value from an ANCOVA (analysis of covariance) model for per-participant/partner percentage of 'yes' response to SEP5 or pSEP3; model includes terms for baseline severity according to IIEF-EF domain score (mild/moderate/severe), treatment and pooled site.
Correlation of EF change to study outcomes
w This analysis included participants with both baseline and at least one post-baseline measurement. z This analysis included participants with at least one successful intercourse attempt during the treatment period. Participant overall sexual satisfaction (SEP5) adjusted for participantreported successful intercourse attempts (SEP3), and partner overall sexual satisfaction (pSEP3) adjusted for participant-reported successful intercourse attempts (SEP3).
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Correlation analysis was performed with IIEF-EF domain scores rather than with SEP3 results; however, erection hardness (SEP4) and OS measures (SEP5 and pSEP3) were improved for tadalafiltreated participants and their partners when all intercourse attempts or only successful intercourse attempts were included (Figures 3 and 4 ).
Safety
Treatment with tadalafil was generally well tolerated. Most adverse events were mild to moderate in severity and were consistent with previous studies of once daily dosing. 9, 19 The percentage of participants who completed the study was slightly higher in the tadalafil (92%) vs placebo (82%) group, and the most common reason for discontinuation was participant decision (tadalafil, 8 participants; placebo, 12 participants). No participant in the placebo group and three (1%) participants in the tadalafil group discontinued owing to adverse events.
Discussion
Many men with ED experience sexual dissatisfaction, anxiety, reduced self-esteem and self-confidence, diminished quality of life, relationship strain and/or depressive symptoms. [20] [21] [22] These psychosocial aspects of ED influence subjects' and partners' Placebo (n=74) Tadalafil (n=222) Placebo (n=48) Figure 4 Satisfaction with erection hardness (participant SEP4) and SEP4 adjusted for SEP3 positive. SEP, sexual encounter profile; SEP4, Were you satisfied with the hardness of your erection? SEP3, Did your erection last long enough for you to have successful intercourse? *P-value o0.001 (compared to placebo). y P-value o0.001; P-value from an ANCOVA (analysis of covariance) model for perparticipant percentage of 'yes' response to SEP4; model includes terms for baseline severity according to IIEF-EF domain score (mild/ moderate/severe), treatment and pooled site.
w This analysis included participants with both baseline and at least one post-baseline measurement.
z This analysis included participants with at least one successful intercourse attempt during the treatment period. w Participant satisfaction with erection hardness (SEP4), adjusted for participant-reported successful intercourse attempts (SEP3). Sexual satisfaction of participants and partners AD Seftel et al attitudes toward treatment, and create complex dynamics in the couple's relationship that are not directly affected by ED treatment. 23 As a man's satisfaction with treatment will influence his treatment compliance and medication preference, clinicians' consideration of the patient in the context of his relationship to his partner could increase the likelihood of treatment success. 1 As ED is a shared sexual dysfunction, consideration of partners in treatment decisions brings balance to both sides of the ED-treatment equation.
In both treatment groups in this study, changes in participant's EF, and changes in confidence, selfesteem and overall relationship (SEAR), as well as multiple satisfaction measures were positively correlated and statistically significant. Changes in men's EF and changes in partner's satisfaction also correlated positively. This evidence supports the association between EF and participant's and partner's satisfaction, and suggests that ED treatment improves many facets of a man's mental well-being, a couple's relationship and his partner's sexual satisfaction.
Women in both treatment groups reported greater baseline OS than did participants, resulting in higher OS scores at the end of the study for partners than for participants; however, the mean change from baseline was greater for the participants. This result has been observed in other studies, suggesting that changes in sexual satisfaction scores may be more important in interpreting study results than end point scores. 6 When only participant-reported successful intercourse attempts were considered ('yes' response to SEP3), higher OS scores were also reported by partners. The OS scores for tadalafiltreated participants improved more from baseline than for their partners, adding further support to the connection between men's EF and sexual satisfaction.
Previous studies with tadalafil or other phosphodiesterase 5 inhibitors have shown that ED treatment significantly improves participants' sexual satisfaction and the satisfaction of their untreated female partners. [24] [25] [26] This is the first report, however, of these measures after treatment with tadalafil 5 mg once daily, and these data support the paradigm that providing an effective treatment for men with ED can also benefit their female partners and increase their sexual satisfaction.
A potential limitation of the study design was the inclusion criterion that required female partners without primary sexual dysfunction, which was used to limit the confounding effect that a range of baseline female sexual function would have on study measures. This criterion may have eliminated a substantial number of couples wherein the woman was negatively impacted by her partner's ED. The need to enroll couples willing and eligible to participate rather than just men with ED may have also contributed to the proportion of men enrolled with mild ED and at the lower end of the age range that is typically reported for men affected by ED. 27 Future studies should provide the opportunity to evaluate women with some degree of sexual dysfunction.
In addition, homosexual men were not included in this study because the measures were validated for sexual intercourse, defined as vaginal penetration and/or including vaginal penetration within the question. If homosexual couples were included in this study, the ability to generalize the results may have actually been reduced, because the data would not be consistent with the validation and definition of the measurements. Sexual satisfaction of participants and partners AD Seftel et al
Another possible limitation of the study design was that treatment consisted of prescribing a medication, which is the current common model of treating ED, whereas a combination of pharmacological and psychological treatments may have been beneficial. As reported by Althof 28 , ED may result in significant psychosocial issues for both participants and partners, which may be more effectively addressed by a combination treatment model.
The primary objective of this study was to evaluate the efficacy of tadalafil 5 mg once daily in improving EF in men with ED and the impact of treatment on the SQoL of participants and their partners. Consistent with other studies, tadalafil significantly improved the EF and was generally well tolerated. 9, 19, 29 Unique end points included in this study were measures to evaluate the effect of treatment on participant's psychosocial outcomes and sexual satisfaction of participants and their partners, who were not directly treated.
In conclusion, tadalafil 5 mg once daily significantly improved participant and partner treatment and sexual satisfaction, as well as SEAR measures of sexual relationship, confidence, self-esteem and overall relationship. These improvements were positively correlated with improvements in EF.
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